These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9182984)

  • 1. Prospective study of sex hormone levels and risk of prostate cancer.
    Wolk A; Andersson SO; Bergström R
    J Natl Cancer Inst; 1997 Jun; 89(11):820. PubMed ID: 9182984
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective study of sex hormone levels and risk of prostate cancer.
    Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
    J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
    Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating steroid hormones and the risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley W; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):86-91. PubMed ID: 16434592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.
    Salonia A; Abdollah F; Capitanio U; Suardi N; Briganti A; Gallina A; Colombo R; Ferrari M; Castagna G; Rigatti P; Montorsi F
    Clin Cancer Res; 2012 Jul; 18(13):3648-57. PubMed ID: 22589393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer.
    Barrett-Connor E; Garland C; McPhillips JB; Khaw KT; Wingard DL
    Cancer Res; 1990 Jan; 50(1):169-73. PubMed ID: 2293551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
    García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
    Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding capacity of testosterone-estradiol-binding globulin (TeBG), total and calculated unbound concentrations of testosterone in patients with carcinoma of the prostate treated with orchidectomy or estrogens.
    Damber JE; Bergman B; Södergård R; Tomić R
    J Endocrinol Invest; 1983 Apr; 6(2):91-4. PubMed ID: 6683289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
    Chen C; Weiss NS; Stanczyk FZ; Lewis SK; DiTommaso D; Etzioni R; Barnett MJ; Goodman GE
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1410-6. PubMed ID: 14693730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of prostate growth.
    Coffey DS; Isaacs JT
    Urology; 1981 Mar; 17(Suppl 3):17-24. PubMed ID: 6163242
    [No Abstract]   [Full Text] [Related]  

  • 11. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study.
    Stattin P; Lumme S; Tenkanen L; Alfthan H; Jellum E; Hallmans G; Thoresen S; Hakulinen T; Luostarinen T; Lehtinen M; Dillner J; Stenman UH; Hakama M
    Int J Cancer; 2004 Jan; 108(3):418-24. PubMed ID: 14648709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association of obesity and insulin resistance with serum testosterone, sex hormone binding globulin and estradiol in older males].
    Barud W; Piotrowska-Swirszcz A; Ostrowski S; Palusiński R; Makaruk B
    Pol Merkur Lekarski; 2005 Nov; 19(113):634-7. PubMed ID: 16498800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
    de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
    Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Estradiol, luteinizing hormone, testosterone and sex hormone-binding globulin in the clomiphene-induced menstrual cycle].
    Huber H; Schurz B; Spona J
    Gynakol Rundsch; 1985; 25(1):23-30. PubMed ID: 4038961
    [No Abstract]   [Full Text] [Related]  

  • 15. Does rifampicin increase serum levels of testosterone and oestradiol by inducing sex hormone binding globulin capacity?
    Brodie MJ; Boobis AR; Gill M; Mashiter K
    Br J Clin Pharmacol; 1981 Sep; 12(3):431-3. PubMed ID: 7197544
    [No Abstract]   [Full Text] [Related]  

  • 16. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.
    Smith MR
    Clin Cancer Res; 2007 Jan; 13(1):241-5. PubMed ID: 17200361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men.
    Gyawali P; Martin SA; Heilbronn LK; Vincent AD; Taylor AW; Adams RJT; O'Loughlin PD; Wittert GA
    Acta Diabetol; 2018 Aug; 55(8):861-872. PubMed ID: 29845345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men.
    Vikan T; Schirmer H; Njølstad I; Svartberg J
    Eur J Endocrinol; 2010 Apr; 162(4):747-54. PubMed ID: 20061333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage.
    Jentzmik F; Schnoeller TJ; Cronauer MV; Steinestel J; Steffens S; Zengerling F; Al Ghazal A; Schrader MG; Steinestel K; Schrader AJ
    Int J Urol; 2014 Oct; 21(10):980-6. PubMed ID: 24865433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.